Alnylam Pharmaceuticals Inc. said Wednesday morning that a 12-month trial of one of its RNA-blocking drugs met its primary goal, propelling its stock up more than 50% as of 10 a.m.
The Cambridge-based drugmaker (Nasdaq: ALNY) said the late-stage study of patisiran — a drug already approved and marketed under the name Onpattro for people with a rare, fatal heart condition — did significantly better than a placebo in treating patients with a more common heart condition, called transthyretin-mediated…
